June 2026
PTSD
What June 2026's 13 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 13 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research on PTSD in June 2026 focused heavily on ketamine and psychedelic-assisted therapies, with mixed results: MDMA-assisted psychotherapy showed significant moderate-to-large symptom reductions, while ketamine's effects were inconsistent—some studies found large improvements, others found small or non-significant effects, and acute trauma use may worsen symptoms. Other interventions like mindfulness and imagery rehearsal therapy showed short-term benefits, but durability and long-term outcomes remain unclear. Overall, the evidence is heterogeneous and limited by small samples, poor study quality, and unresolved methodological challenges.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects. 2026 | systematic review and individual participant data meta-analysis | 533 | Supports | Higher baseline PTSD severity, more psychotherapy and ketamine sessions, and shorter treatment duration were associated with greater symptom reduction after combined ketamine and psychotherapy. |
| At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States. 2026 | retrospective observational study | 3870 | Supports | At-home subcutaneous ketamine was associated with large, clinically meaningful reductions in depression, anxiety, and PTSD symptoms with low adverse events. |
| Efficacy of imagery rehearsal therapy in the treatment of traumatic nightmares in youth with complex post-traumatic stress disorder. 2026 | randomized controlled trial | Supports | Imagery rehearsal therapy reduced traumatic nightmare frequency and distress in youth with complex PTSD. | |
| Efficacy of Mindfulness-Based Interventions for Treating Anxiety in PTSD Patients 2026 | controlled clinical trial | 120 | Supports | Mindfulness-based intervention added to routine psychological support was associated with clinically meaningful short-term reductions in anxiety and PTSD symptoms among trauma-exposed adults. |
| Acute pretrauma ethanol exacerbates PTSD-like phenotype in rats and is reversed by early intranasal ketamine 2026 | observational cohort with experimental manipulation | Mixed | Pre-trauma ethanol exposure increased PTSD-like phenotype prevalence and hippocampal dendritic retraction, while early post-trauma intranasal ketamine reduced these effects. | |
| Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 358 | Mixed | MDMA-assisted psychotherapy showed a significant moderate-to-large reduction in PTSD symptom severity, while ketamine and cannabidiol did not show significant or clear benefit. |
| Factors associated with post-traumatic growth in severe COVID-19 patients discharged from intensive care: the influence of near-death experiences. 2026 | cross-sectional, monocentric study | 59 | Supports | Post-traumatic growth was associated with the presence of a near-death experience, intense and intrusive memories, and higher PTSD symptom levels. |
| The impact of ketamine on posttraumatic stress disorder (PTSD) symptomatology in trauma-exposed populations: a narrative review. 2026 | narrative review | Mixed | Ketamine's effect on PTSD depends on dose and timing: a single 0.5 mg/kg infusion may reduce symptoms within 24 hours, but acute trauma use may worsen dissociation and stress responses. | |
| From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | commentary | Unclear | Argues that unresolved scientific challenges—including blinding difficulties, expectancy effects, and lack of active comparators—are central to interpreting MDMA-assisted psychotherapy for PTSD, and that broader recovery indicators beyond symptom reduction are needed. | |
| Investigational drugs in PTSD. 2026 | review | Mixed | Rapid-acting interventions like ketamine and MDMA-assisted psychotherapy represent major advances in PTSD therapeutics, but many mechanistically plausible candidates have failed in late-stage trials due to high placebo responses, patient heterogeneity, and translational gaps. | |
| Characteristics of Sleep Paralysis and Its Association With PTSD, Stress, and Other Lifestyle Variables Among the Population of Pakistan, a Cross-Sectional Study. 2026 | cross-sectional study | 412 | Supports | Sleep paralysis episodes are significantly associated with stress, PTSD, caffeine intake, and smoking. |
| Circuit-informed modulation of traumatic memory in PTSD: integrating extinction, suppression, and reconsolidation. 2026 | review | Unclear | Argues that integrating extinction reinforcement with voluntary memory control and reconsolidation editing offers a coherent route to more durable relief from traumatic memories in PTSD. | |
| Clinical Outcomes of Ketamine Therapy for Depression, Anxiety, and PTSD in Post-TBI Patients 2026 | retrospective chart review | 35 | Supports | Ketamine treatment was associated with large effect sizes (32.7% to 65.6% symptom reduction) and 72% response and 45% remission rates in TBI patients, with parenteral routes outperforming oral. |
Higher baseline PTSD severity, more psychotherapy and ketamine sessions, and shorter treatment duration were associated with greater symptom reduction after combined ketamine and psychotherapy.
systematic review and individual participant data meta-analysis Sample size: 533
At-home subcutaneous ketamine was associated with large, clinically meaningful reductions in depression, anxiety, and PTSD symptoms with low adverse events.
retrospective observational study Sample size: 3870
Imagery rehearsal therapy reduced traumatic nightmare frequency and distress in youth with complex PTSD.
randomized controlled trial
Mindfulness-based intervention added to routine psychological support was associated with clinically meaningful short-term reductions in anxiety and PTSD symptoms among trauma-exposed adults.
controlled clinical trial Sample size: 120
Pre-trauma ethanol exposure increased PTSD-like phenotype prevalence and hippocampal dendritic retraction, while early post-trauma intranasal ketamine reduced these effects.
observational cohort with experimental manipulation
MDMA-assisted psychotherapy showed a significant moderate-to-large reduction in PTSD symptom severity, while ketamine and cannabidiol did not show significant or clear benefit.
systematic review and meta-analysis Sample size: 358
Post-traumatic growth was associated with the presence of a near-death experience, intense and intrusive memories, and higher PTSD symptom levels.
cross-sectional, monocentric study Sample size: 59
Ketamine's effect on PTSD depends on dose and timing: a single 0.5 mg/kg infusion may reduce symptoms within 24 hours, but acute trauma use may worsen dissociation and stress responses.
narrative review
Argues that unresolved scientific challenges—including blinding difficulties, expectancy effects, and lack of active comparators—are central to interpreting MDMA-assisted psychotherapy for PTSD, and that broader recovery indicators beyond symptom reduction are needed.
commentary
Rapid-acting interventions like ketamine and MDMA-assisted psychotherapy represent major advances in PTSD therapeutics, but many mechanistically plausible candidates have failed in late-stage trials due to high placebo responses, patient heterogeneity, and translational gaps.
review
Sleep paralysis episodes are significantly associated with stress, PTSD, caffeine intake, and smoking.
cross-sectional study Sample size: 412
Argues that integrating extinction reinforcement with voluntary memory control and reconsolidation editing offers a coherent route to more durable relief from traumatic memories in PTSD.
review
Ketamine treatment was associated with large effect sizes (32.7% to 65.6% symptom reduction) and 72% response and 45% remission rates in TBI patients, with parenteral routes outperforming oral.
retrospective chart review Sample size: 35
Points of agreement
- Ketamine and MDMA-assisted psychotherapy show promise for PTSD symptom reduction, but effects vary by dose, timing, and route.
- Mindfulness-based interventions and imagery rehearsal therapy show short-term benefits for PTSD symptoms and nightmares.
- Higher baseline PTSD severity and more treatment sessions are associated with greater improvement in ketamine-assisted psychotherapy.
- Rapid-acting interventions are considered major advances, but durability and long-term outcomes remain uncertain.
Conflicts
- Ketamine's efficacy is inconsistent: some studies report large effects, while a meta-analysis found small non-significant effects.
- Acute trauma use of ketamine may worsen dissociation and stress responses, conflicting with its therapeutic benefits in chronic PTSD.
- MDMA-assisted psychotherapy shows significant efficacy in one meta-analysis, but a commentary highlights unresolved methodological issues that may inflate effects.
Gaps
- Durability of treatment effects beyond short-term follow-up is largely unstudied.
- Blinding and expectancy effects are unresolved in psychedelic-assisted psychotherapy trials.
- Most studies have small sample sizes or poor quality, limiting generalizability.
- Optimal dosing, timing, and patient selection for ketamine therapy remain unclear.
- Long-term safety and scalability of at-home ketamine protocols are not well established.